Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Colonic Neoplasms 1Carcinoma, Islet Cell 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Cytokines × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡